bimatoprost
Selected indexed studies
- Bimatoprost Implant: First Approval. (Drugs Aging, 2020) [PMID:32447639]
- Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. (Drug Des Devel Ther, 2025) [PMID:39906697]
- Intracameral sustained release bimatoprost implants (Durysta). (Semin Ophthalmol, 2022) [PMID:34586961]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bimatoprost Implant: First Approval. (2020) pubmed
- Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. (2025) pubmed
- Intracameral sustained release bimatoprost implants (Durysta). (2022) pubmed
- Bimatoprost: a novel antiglaucoma agent. (2004) pubmed
- Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. (2017) pubmed
- Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. (2005) pubmed
- Bimatoprost - a review. (2009) pubmed
- Bimatoprost. (2005) pubmed
- Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. (2009) pubmed
- Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. (2009) pubmed